Treatment with the FGFR inhibitor erdafitinib in patients with metastatic bladder cancers marked by mutations in the FGFR3 gene resulted in a 40% overall response rate (ORR) and was well-tolerated, according to an international Phase II trial led by The University of Texas MD Anderson Cancer Center.
source https://www.lifetechnology.com/blogs/life-technology-news-blog/targeted-therapy-erdafitinib-effective-for-patients-with-advanced-bladder-cancer-and-specific-gene-mutations